3β-Hydroxysteroid Dehydrogenase Type 2 (3βHSD2) Deficiency due to a Novel Compound Heterozygosity of a Missense Mutation (p.Thr259Met) and Frameshift Deletion (p.Lys273ArgFs*7) in an Undervirilized Infant Male with Salt Wasting
Sexual Development · 2022 · 16 (1) · 64-69
DOI: 10.1159/000519062 ↗Kurz gefasst
Fallbericht in der Zeitschrift Sexual Development, online erschienen am 08.10.2021. Verfasst von Sofia Leka-Emiri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology-Growth and Development, "P&A KYRIAKOU" Children's Hospital, Athens, Greece. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Deficiency of 3β-hydroxysteroid dehydrogenase type 2 (3βHSD2) is a rare type of congenital adrenal hyperplasia (CAH), causing impaired steroid hormone production in both adrenals and gonads. Phenotype ranges, according to the genetic defect, from the salt-wasting form in both sexes to undervirilization in males and virilization in females. We present a 13-month-old male infant who was admitted to the hospital with signs of adrenocortical insufficiency and genital ambiguity. Clinical presentation, hormonal profile, laboratory evaluation, and karyotype were suggestive of the salt-wasting form of CAH due to 3βHSD2 deficiency. Mutational analysis revealed a missense mutation c.776C>T (p.Thr259Met), inherited by the mother, and a frameshift deletion c.818-819delAA (p.Lys273ArgFs*7), inherited by the father. Both mutations are considered pathogenic. To our knowledge this is the first case of an undervirilized male infant with salt wasting bearing this pathogenic frameshift deletion p.Lys273ArgFs*7 in compound heterozygosity with the missense mutation p.Thr259Met.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology-Growth and Development, "P&A KYRIAKOU" Children's Hospital, Athens, Greece.
- Biochemistry-Hormonology Laboratory, Robert-Debré Hospital, Paris Diderot University, Paris, France.
- Division of Biochemistry-Hormonology, "P&A KYRIAKOU" Children's Hospital, Athens, Greece.
Zitieren
APA
Leka-Emiri, S., Taibi, L., Mavroeidi, V., Vlachopapadopoulou, E. A., Kafetzi, M., Michalacos, S., & de Roux, N. (2022). 3β-Hydroxysteroid Dehydrogenase Type 2 (3βHSD2) Deficiency due to a Novel Compound Heterozygosity of a Missense Mutation (p.Thr259Met) and Frameshift Deletion (p.Lys273ArgFs*7) in an Undervirilized Infant Male with Salt Wasting. Sexual Development, 16(1), 64-69. https://doi.org/10.1159/000519062
Vancouver
Leka-Emiri S, Taibi L, Mavroeidi V, Vlachopapadopoulou EA, Kafetzi M, Michalacos S, et al. 3β-Hydroxysteroid Dehydrogenase Type 2 (3βHSD2) Deficiency due to a Novel Compound Heterozygosity of a Missense Mutation (p.Thr259Met) and Frameshift Deletion (p.Lys273ArgFs*7) in an Undervirilized Infant Male with Salt Wasting. Sexual Development. 2022;16(1):64-69. doi:10.1159/000519062
BibTeX
@article{LekaEmiri2022,
author = {Leka-Emiri, Sofia and Taibi, Ludmia and Mavroeidi, Vasiliki and Vlachopapadopoulou, Elpis A and Kafetzi, Maria and Michalacos, Stefanos and de Roux, Nicolas},
title = {3β-Hydroxysteroid Dehydrogenase Type 2 (3βHSD2) Deficiency due to a Novel Compound Heterozygosity of a Missense Mutation (p.Thr259Met) and Frameshift Deletion (p.Lys273ArgFs*7) in an Undervirilized Infant Male with Salt Wasting},
journal = {Sexual Development},
year = {2022},
volume = {16},
number = {1},
pages = {64--69},
doi = {10.1159/000519062}
}
EUVIMED